Skip to content

Three Techniques for Ultrasound Guided Axillary Brachial Plexus Block

Prospective Randomized Study of Three Different Techniques for Ultrasound Guided Axillary Brachial Plexus Block

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02073383
Enrollment
313
Registered
2014-02-27
Start date
2013-08-31
Completion date
2015-03-31
Last updated
2014-02-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hand Surgery

Keywords

Axillary brachial plexus block, Ultrasound, Bupivacaine

Brief summary

The brachial plexus block is an anesthetic technique often used for surgical procedures of the upper limb. The brachial plexus block through the axilla (BPVA) is one of the techniques most commonly used to obtain regional anesthesia of the upper limbs, being performed by anesthesia of the terminal branches of the brachial plexus, which would be the ulnar, median, radial and musculocutaneous nerves. With the aid of ultrasound , two techniques can be used to perform the BPVA . The first , known as multiple puncture technique , the local anesthetic is deposited around each nerve that want to block . This technique is most commonly used to perform the BPVA . The second technique , known as 2 injections , local anesthetic is deposited below the axillary artery and around the musculocutaneous nerve . This technique has been proposed to try to reduce the execution time of anesthesia . Studies actually show that the technique of 2 injections showed less time to perform the block, with the same success rate. However, the technique of 2 injections showed a longer latency and higher rate of vascular puncture . (14) In order to perform a procedure with shorter execution time , without changing the latency, success rate and ensuring patient safety , the investigators designed this protocol to evaluate three techniques for performing the ultrasound- guided axillary brachial plexus block.

Interventions

Sponsors

Federal University of São Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Informed consent signed by the patient (IC) * Indication for brachial plexus block for anesthesia and analgesia in candidates for hand surgical procedures * ASA physical status I, II or III according to the American Association of Anesthesiology.

Exclusion criteria

* Cognitive impairment or psychiatric disease * Active infection condition at the puncture site of the block * Bleeding disorders * History of allergy to bupivacaine.

Design outcomes

Primary

MeasureTime frameDescription
The primary outcome is to compare the efficacy of the three different techniques for ultrasound guided axillary brachial plexus blockThe primary outcome will be measured at the same day of the procedure.The brachial plexus block is performed through the axilla , with the aid of ultrasound and a peripheral nerve stimulator with the patient in the supine position. The needle that will be used is 22G x 50 mm . After disinfection and skin antisepsis with chlorhexidine , tha puncture site will be infiltrated with 1% lidocaine . Furthermore, musculocutaneous nerve will be blockade with 10 ml of 0.375% bupivacaine for all patients. Patients will be divided into three groups : Group A: 30 ml of 0.375% bupivacaine will be injected around the artery . If this were a clock, would deposit 7,5 ml of anesthetic in positions 0, 3, 6 and 9 . Group 2 injections : 30 ml of bupivacaine 0.375 % below the artery will be injected in the 6 o'clock position . Group M : 10 ml of bupivacaine 0.375 % will be injected

Secondary

MeasureTime frameDescription
Block Latency30 minutesLatency time of the blockade , defined as the time between the end of injection of local anesthetic will be noted.

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026